Related Experiment Video
Updated: Aug 11, 2026
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
Published on: June 23, 2011
Pradimicin A inhibition of human immunodeficiency virus: attenuation by mannan
A Tanabe-Tochikura1, T S Tochikura, O Yoshida
1Department of Virology and Parasitology, Yamaguchi University School of Medicine, Japan.
Abstract:
The mechanism of action of a novel anti-HIV antibiotic, pradimicin A, has been studied using cell-free (MT-4 cells) and cell to cell (MOLT-4 and MOLT-4/HIVHTLV-3B cells) HIV infection systems. The data indicate that (1) preincubation of the cells with HIV at 0 degrees for 1 hr, followed by the addition of pradimicin A and further incubation at 37 degrees, resulted in a complete inhibition of infection while preincubation at 37 degrees did not. Similar data were obtained with the coculture between MOLT-4 and MOLT-4/HIV cells. (2) Virus treated with pradimicin A followed by washing did not show any inhibition on subsequent HIV binding to cells. (3) The inhibitory effect of pradimicin A on HIV infection was prevented by mannan but not by other sugars tested. Mannan, however, did not interfere with the anti-HIV activity of other known inhibitors. (4) Use of EGTA suggested that pradimicin A required Ca ions to exert its anti-HIV activity. These data imply that pradimicin A inhibits an early step in HIV infection, probably through its binding to mannose residues of HIV glycoprotein.
Insights
Pradimicin A, a novel anti-HIV antibiotic, inhibits early HIV infection steps. Its activity requires calcium ions and appears to involve binding to mannose residues on HIV glycoproteins.
Area of Science:
- Virology
- Microbiology
- Drug Discovery
Background:
- Human Immunodeficiency Virus (HIV) remains a significant global health challenge.
- Novel therapeutic strategies are crucial for combating HIV infection.
- Pradimicin A is a novel antibiotic with potential anti-HIV activity.
Purpose of the Study:
- To elucidate the mechanism of action of pradimicin A against HIV.
- To investigate the specific stage of HIV infection inhibited by pradimicin A.
- To identify factors influencing pradimicin A's anti-HIV efficacy.
Main Methods:
- Utilized cell-free and cell-to-cell HIV infection systems (MT-4, MOLT-4, MOLT-4/HIVHTLV-3B cells).
- Assessed inhibition at different preincubation temperatures and conditions.
- Investigated the effect of pradimicin A on viral binding post-treatment.
- Examined the role of mannan and calcium ions (Ca ions) in pradimicin A's activity.
Main Results:
- Pradimicin A completely inhibited HIV infection when cells were preincubated with HIV at 0°C before drug addition.
- Pradimicin A did not inhibit subsequent HIV binding to cells after virus treatment and washing.
- Mannan, but not other sugars, prevented pradimicin A's inhibitory effect, suggesting interaction with mannose residues.
- EGTA studies indicated that Ca ions are required for pradimicin A's anti-HIV activity.
Conclusions:
- Pradimicin A inhibits an early step in the HIV life cycle, likely before viral binding.
- The mechanism involves interaction with mannose residues on HIV glycoproteins.
- Calcium ions are essential for pradimicin A's anti-HIV efficacy.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
01:25Inhibitors Of Virion Release
01:19Inhibitors of Virion Maturation and Assembly